よむ、つかう、まなぶ。
資料４－２ 日本版抗コリン薬リスクスケール (41 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40741.html |
| 出典情報 | 高齢者医薬品適正使用検討会（第18回 6／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
54.
Gnjidic D, Couteur DGL, Abernethy DR, Hilmer SN. Drug burden index and beers criteria: impact on
functional outcomes in older people living in self‐care retirement villages. The Journal of Clinical
Pharmacology. 2012;52(2):258-65.
55.
Landi F, Russo A, Liperoti R, Cesari M, Barillaro C, Pahor M, et al. Anticholinergic drugs and physical
function among frail elderly population. Clinical Pharmacology & Therapeutics. 2007;81(2):235-41.
56.
Akgün Ö, Oudshoorn C, Mattace-Raso FU, Egberts A. Anticholinergic Drug Use on Admission and the
Risk of In-Hospital Falls in Older Hospitalized Patients. Clinical interventions in aging. 2022:277-85.
57.
Jean-Bart E, Moutet C, Dauphinot V, Krolak-Salmon P, Mouchoux C. Exposure to anticholinergic and
sedative medicines as indicators of high-risk prescriptions in the elderly. International Journal of Clinical
Pharmacy. 2017;39:1237-47.
58.
Suehs BT, Caplan EO, Hayden J, Ng DB, Gaddy RR. The relationship between anticholinergic
exposure and falls, fractures, and mortality in patients with overactive bladder. Drugs & Aging. 2019;36:95767.
59.
Marcum ZA, Wirtz HS, Pettinger M, LaCroix AZ, Carnahan R, Cauley JA, et al. Anticholinergic
medication use and falls in postmenopausal women: findings from the women’s health initiative cohort
study. BMC geriatrics. 2016;16:1-9.
60.
Berdot S, Bertrand M, Dartigues J-F, Fourrier A, Tavernier B, Ritchie K, et al. Inappropriate
medication use and risk of falls–a prospective study in a large community-dwelling elderly cohort. BMC
geriatrics. 2009;9:1-10.
61.
Cetinel B, Onal B, Gultekin MH, Guzelsoy M, Turegun FA, Dincer M. Which antimuscarinic agents
used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
International Urology and Nephrology. 2019;51:417-24.
62.
Bharucha A, Isowa H, Hiro S, Guan Z. Differential effects of selective and non‐selective muscarinic
antagonists on gastrointestinal transit and bowel function in healthy women. Neurogastroenterology &
Motility. 2013;25(1):e35-e43.
63.
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, et al. Long‐term safety and
efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal
response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study).
International Journal of Urology. 2019;26(3):342-52.
64.
Thiwan S, Drossman DA, Morris CB, Dalton C, Toner BB, Diamant NE, et al. Not all side effects
associated with tricyclic antidepressant therapy are true side effects. Clinical Gastroenterology and
Hepatology. 2009;7(4):446-51.
65.
Homma Y, Yamaguchi O. Long‐term safety, tolerability, and efficacy of the novel anti‐muscarinic
agent imidafenacin in Japanese patients with overactive bladder. International journal of urology.
2008;15(11):986-91.
66.
Kakkar M, de Souza Valentim EC, Barmak AB, Arany S. Potential association of anticholinergic
medication intake and caries experience in young adults with xerostomia. Journal of Dental Sciences.
2023;18(4):1693-8.
67.
Tiisanoja A, Syrjälä AM, Komulainen K, Lampela P, Hartikainen S, Taipale H, et al. Anticholinergic
burden and dry mouth among Finnish, community‐dwelling older adults. Gerodontology. 2018;35(1):3-10.
68.
Castejón-Hernández S, Latorre-Vallbona N, Molist-Brunet N, Cubí-Montanyà D, Espaulella-Panicot J.
Association between anticholinergic burden and oropharyngeal dysphagia among hospitalized older adults.
Aging Clinical and Experimental Research. 2021;33:1981-5.
69.
Prado-Mel E, Ciudad-Gutiérrez P, Rodríguez-Ramallo H, Sánchez-Fidalgo S, Santos-Ramos B, VillalbaMoreno A. Association between anticholinergic activity and xerostomia and/or xerophthalmia in the elderly:
systematic review. BMC Pharmacology and Toxicology. 2022;23(1):94.
70.
Chen S-F, Chuang Y-C, Wang C-C, Liao C-H, Kuo H-C. Therapeutic efficacy and cognitive adverse
events of overactive bladder medication in patients with central nervous system Disorders—A cohort study.
Journal of the Formosan Medical Association. 2022;121(10):2101-8.
41
Gnjidic D, Couteur DGL, Abernethy DR, Hilmer SN. Drug burden index and beers criteria: impact on
functional outcomes in older people living in self‐care retirement villages. The Journal of Clinical
Pharmacology. 2012;52(2):258-65.
55.
Landi F, Russo A, Liperoti R, Cesari M, Barillaro C, Pahor M, et al. Anticholinergic drugs and physical
function among frail elderly population. Clinical Pharmacology & Therapeutics. 2007;81(2):235-41.
56.
Akgün Ö, Oudshoorn C, Mattace-Raso FU, Egberts A. Anticholinergic Drug Use on Admission and the
Risk of In-Hospital Falls in Older Hospitalized Patients. Clinical interventions in aging. 2022:277-85.
57.
Jean-Bart E, Moutet C, Dauphinot V, Krolak-Salmon P, Mouchoux C. Exposure to anticholinergic and
sedative medicines as indicators of high-risk prescriptions in the elderly. International Journal of Clinical
Pharmacy. 2017;39:1237-47.
58.
Suehs BT, Caplan EO, Hayden J, Ng DB, Gaddy RR. The relationship between anticholinergic
exposure and falls, fractures, and mortality in patients with overactive bladder. Drugs & Aging. 2019;36:95767.
59.
Marcum ZA, Wirtz HS, Pettinger M, LaCroix AZ, Carnahan R, Cauley JA, et al. Anticholinergic
medication use and falls in postmenopausal women: findings from the women’s health initiative cohort
study. BMC geriatrics. 2016;16:1-9.
60.
Berdot S, Bertrand M, Dartigues J-F, Fourrier A, Tavernier B, Ritchie K, et al. Inappropriate
medication use and risk of falls–a prospective study in a large community-dwelling elderly cohort. BMC
geriatrics. 2009;9:1-10.
61.
Cetinel B, Onal B, Gultekin MH, Guzelsoy M, Turegun FA, Dincer M. Which antimuscarinic agents
used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
International Urology and Nephrology. 2019;51:417-24.
62.
Bharucha A, Isowa H, Hiro S, Guan Z. Differential effects of selective and non‐selective muscarinic
antagonists on gastrointestinal transit and bowel function in healthy women. Neurogastroenterology &
Motility. 2013;25(1):e35-e43.
63.
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, et al. Long‐term safety and
efficacy of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal
response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study).
International Journal of Urology. 2019;26(3):342-52.
64.
Thiwan S, Drossman DA, Morris CB, Dalton C, Toner BB, Diamant NE, et al. Not all side effects
associated with tricyclic antidepressant therapy are true side effects. Clinical Gastroenterology and
Hepatology. 2009;7(4):446-51.
65.
Homma Y, Yamaguchi O. Long‐term safety, tolerability, and efficacy of the novel anti‐muscarinic
agent imidafenacin in Japanese patients with overactive bladder. International journal of urology.
2008;15(11):986-91.
66.
Kakkar M, de Souza Valentim EC, Barmak AB, Arany S. Potential association of anticholinergic
medication intake and caries experience in young adults with xerostomia. Journal of Dental Sciences.
2023;18(4):1693-8.
67.
Tiisanoja A, Syrjälä AM, Komulainen K, Lampela P, Hartikainen S, Taipale H, et al. Anticholinergic
burden and dry mouth among Finnish, community‐dwelling older adults. Gerodontology. 2018;35(1):3-10.
68.
Castejón-Hernández S, Latorre-Vallbona N, Molist-Brunet N, Cubí-Montanyà D, Espaulella-Panicot J.
Association between anticholinergic burden and oropharyngeal dysphagia among hospitalized older adults.
Aging Clinical and Experimental Research. 2021;33:1981-5.
69.
Prado-Mel E, Ciudad-Gutiérrez P, Rodríguez-Ramallo H, Sánchez-Fidalgo S, Santos-Ramos B, VillalbaMoreno A. Association between anticholinergic activity and xerostomia and/or xerophthalmia in the elderly:
systematic review. BMC Pharmacology and Toxicology. 2022;23(1):94.
70.
Chen S-F, Chuang Y-C, Wang C-C, Liao C-H, Kuo H-C. Therapeutic efficacy and cognitive adverse
events of overactive bladder medication in patients with central nervous system Disorders—A cohort study.
Journal of the Formosan Medical Association. 2022;121(10):2101-8.
41